Welcome to the Huang Lab
Posted on June 11, 2018
Our laboratory integrates nanoscience and photobiology to help fight diseased improve daily lives. We engineer nanometer-scale objects that allow optical and biophysical manipulation of the disease at various levels. This approach could facilitate the study of physiological barriers to drug delivery, immune tolerance, and molecular drug resistance in living animals and in clinical trials. The established photo-responsive nanotechnology could give a broadly enabling platform for a wide variety of applications, ranging from personalized healthcare to military and security. The Huang lab educational initiatives focus on the development of resources for engineering students and science educators to further their knowledge in photobiology and photochemistry and to foster a sense of community.
Lab Awarded Foundation For Women's Cancer Funding For Work on Ovarian Cancer Photodynamic Treatment
Posted on May 14, 2019
The Huang lab is collaborating with Dr. Dana M. Roque, Assistant Professor of Obstetrics & Gynecology, and Dr. Jocelyn Reader at the University of Maryland School of Medicine to develop targeted, light-activatable nanoparticles for intraperitoneal photodynamic therapy that can be combined with surgical debulking either in the upfront or recurrent setting to eradicate microscopic residual disease.
Thanks to FWC for supporting our work!
New study by Dr. Yan Baglo and Mr. Barry J. Liang published in Cancer Letters
Posted on May 07, 2019
Over the past 30 years, the focus on developing inhibitors of ATP-binding cassette (ABC) transporters to reverse multidrug resistance has provided little to no benefits to cancer patients. Some transporter inhibitors are simply too toxic, while others induce pharmacokinetics changes owing to drug-drug interactions. The lack of clinical success with small-molecule inhibitors has led to a serious setback for the field. There is a desperate need for a conceptual shift to a new strategy that could overcome ABC transporters mediated multidrug resistance in cancer cells. This study by Dr. Baglo and Mr. Liang introduces porphyrin-lipid nanovesicles as a new strategy to escape ABC transporters-mediated efflux of photosensitizing drugs for improved photodynamic therapy outcomes in breast cancer. We also provide new information that FDA-approved benzoporphyrin derivative drug is a substrate for both P-gp and ABCG2, but not MRP1.
For more information, the original article titled 'Porphyrin-lipid Assemblies and Nanovesicles Overcome ABC Transporter-Mediated Photodynamic Therapy Resistance in Cancer Cells' can be read on Science Direct.
New study published in Small
Posted on July 02, 2018
We are pleased to announce that our manuscript titled 'Immobilization of Photoimmunoconjugates on Nanoparticles Leads to Enhanced Light-activated Cancer Cell Cytotoxicity' is publish in Small as a Research Article.
Light-activatable immunoconjugates have recently shown promise for photoimmunotherapy and fluorescence-guided resection in patients suffering from incurable malignancies in early clinical trials. While possessing a number of unique advantages, photoimmunotherapy and fluorescence imaging for oncological diseases can be hampered by therapeutic inefficiency resulting from inadequate photosensitizer delivery.
The study suggests that successful coupling of antibody-photosensitizer photoimmunoconjugates onto polymeric nanoparticles complements the promising attributes of simple photoimmunoconjugates in two significant ways: not only does it improve photosensitizer delivery to tumor, but also offers a forward-looking opportunity to deliver significant and diverse second agents, which can be an imaging agent or a different therapeutic agent, to further enhance the theranostic benefits of photoimmunoconjugates. This approach, based on nanoparticle engineering, achieves effective photoimmunoconjugate delivery and enhances the anti-tumor efficacy in vivo. In addition, this study thoroughly investigated the photochemistry and photophysics (e.g., absorbance, fluorescence quenching, and singlet oxygen yield) of the photoimmunoconjugated nanoplatform, which is of paramount importance for the clinical success of the next generation photoimmunotherapy and imaging.
The original article can be found on Wiley Online Library.
Group meetings, Friday, 12-1pm, AJCH 2223
Happy hour, May 9, 2019
B-day party, May 3, 2019